



Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures and is intended to be regulated as a medical device.

Management Team

Dr. Terrence W. Norchi
President, Chief Executive Officer and Director

Richard E. Davis
Chief Financial Officer

Recent News

Tuesday, February 05, 2019 - 07:50 AM

[Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference](#)

Thursday, December 20, 2018 - 07:50 AM

[Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019](#)

Monday, December 17, 2018 - 07:50 AM

[Arch Therapeutics Receives 510\(k\) Clearance from the US FDA for AC5™ Topical Gel](#)

Thursday, December 06, 2018 - 07:50 AM

[Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event](#)

Tuesday, December 04, 2018 - 07:50 AM

[Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court](#)

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

Contact Information

Arch Therapeutics, Inc.
235 Walnut Street
Suite 6
Framingham, MA 01702

OTCQB: ARTH



Share Price	\$0.36
Volume	398.71k
Shares Outstanding	164,961,849
Market Cap	\$59.39m
52 Week High	\$0.69
52 Week Low	\$0.26

as of 02/21/2019